Project Grant R01CA313953
Award Date 6/18/26
Completion Date 5/31/31
Dollars Obligated $644K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $676,849 to the Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) to substantially enhance MIRDSOFT.org, an open-source radiation dosimetry platform. The award, effective July 1, 2026 through June 30, 2031, supports the development of enhanced dosimetry software and computational tools to enable personalized dose estimation in nuclear medicine and...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 11, 2025, with a completion date of June 30, 2027. This award supports the development of a novel T-cell imaging paradigm utilizing positron emission tomography (PET) agents targeting CD8 and CD4 markers to provide real-time monitoring of endogenous T-cell trafficking, tumor...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $693,290 Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective May 1, 2026, through April 30, 2031. This award supports research to identify spatial tumor microenvironment (TME) signatures for risk stratification in primary melanoma. The project will deliver whole-slide multiplex immunofluorescence (MIF) tissue imaging analysis of 450 stage...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 under the Cancer Treatment Research program (CFDA 93.395) for a five-year project running from April 1, 2026 through March 31, 2031. This project focuses on identifying and targeting tumor regenerative cells (TRCs) that drive treatment resistance and metastatic recurrence in locally advanced rectal cancer (LARC) patients undergoing total neoadjuvant therapy (TNT). Through...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $747,660 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 2, 2026, to develop and validate the RADIANT (Reducing Readmissions Through Innovative Applications of Telemedicine) trial. This five-year initiative, concluding May 31, 2031, combines remote patient monitoring (RPM) with integrative medicine (IM) interventions delivered via...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute For Cancer Research a $452,540 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award supports research to develop and validate electronic nose (e-nose) technology utilizing volatile organic compounds (VOCs) in patient exhalates to predict and assess pathologic response to neoadjuvant therapy in patients with...